Claims for Patent: 9,867,806

Summary for Patent: 9,867,806

Title:	Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
Abstract:	The present invention discloses compounds according to Formula I: ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, L, and the subscript m are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions, and methods of treatment using the same, for the treatment of cystic fibrosis by administering a compound of the invention.
Inventor(s):	De Blieck; Ann (Mechelen, BE), De Munck; Tom Roger Lisette (Mechelen, BE), Joannesse; Caroline Martine Andre (Mechelen, BE), Kelgtermans; Hans (Mechelen, BE), Mammoliti; Oscar (Mechelen, BE), Menet; Christel Jeanne Marie (Mechelen, BE), Tricarico; Giovanni Alessandro (Mechelen, BE), Van der Plas; Steven Emiel (Mechelen, BE)
Assignee:	Galapagos NV (Mechelen, BE)
Application Number:	15/160,639
Patent Claims:	1. A method for the treatment of cystic fibrosis, comprising administering to a mammal afflicted with cystic fibrosis a pharmaceutical composition comprising a pharmaceutically acceptable carrier, a pharmaceutically effective amount of a compound according to Formula I, or pharmaceutically acceptable salt thereof, and at least one additional therapeutic agent selected from the group consisting of aminoglycosides, colistin, azetreonam, ciprofloxacin, azithromycin, hypertonic saline, acetylcysteine, dornase alfa, denufosol, VX-809, VX-661, VX-983, pancreatin, and pancrelipase for the treatment of cystic fibrosis, in an amount sufficient to effect the treatment: ##STR00582## wherein R.sup.1 is H, --CH.sub.3, --CF.sub.3, or cyclopropyl; L is --NR.sup.4--; the subscript m is 0, or 1; R.sup.2 is C.sub.1-4 alkyl or C.sub.1-4 alkyl substituted with one or more independently selected R.sup.5 groups, C.sub.3-7 cycloalkyl, 4-10 membered monocyclic, bridged-, spiro-, or fused bicyclic heterocycloalkyl comprising one or more heteroatoms independently selected from N, O, and S, and optionally substituted with one or more independently selected R.sup.a groups, 5-6 membered monocyclic heterocycloalkenyl comprising one or more heteroatoms independently selected from N, O, and S, and optionally substituted with one or more independently selected R.sup.a groups, C.sub.6-10 mono or bicyclic aryl optionally substituted with one or more independently selected R.sup.b, or 5-10 membered monocyclic or fused bicyclic heteroaryl, comprising one or more heteroatoms independently selected from N, O, and S, and optionally substituted with one or more independently selected R.sup.b; R.sup.3 is C.sub.3-7 cycloalkyl optionally substituted with one or more independently selected R.sup.c groups, 4-7 membered monocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from O, and S, and optionally substituted with R.sup.c, C.sub.6-10 mono or bicyclic aryl optionally substituted with one or more independently selected R.sup.d groups, phenyl fused to a 5-6 membered heterocycloalkyl comprising one or more heteroatoms independently selected from N, O, and S, and optionally substituted with one or more independently selected R.sup.d groups, phenyl fused to a C.sub.5-6 cycloalkyl, optionally substituted with one or more independently selected R.sup.d groups, 5-10 membered mono or fused bicyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S, and optionally substituted with one or more independently selected R.sup.d groups, 5-6 membered monocyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S, fused to a 5-6 membered heterocycloalkyl comprising one or more heteroatoms independently selected from N, O, and S, and optionally substituted with one or more independently selected R.sup.d groups, 5-6 membered monocyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S, fused to a C.sub.5-6 cycloalkyl comprising one or more heteroatoms independently selected from N, O, and S, and optionally substituted with one or more independently selected R.sup.d groups, C.sub.2-6 alkenyl, C.sub.3-6 alkyl, or C.sub.1-6 alkyl substituted with one or more independently selected R.sup.e groups; R.sup.4 is C.sub.1-6 alkyl or C.sub.1-6 alkyl substituted with one or more independently selected R.sup.6 groups, or C.sub.3-7 cycloalkyl; each R.sup.5 is independently selected from halo, OH, --CN, C.sub.1-4 alkoxy, --NR.sup.8eR.sup.8f, C.sub.3-7 cycloalkyl, 6 membered mono or fused bicyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S, and phenyl optionally substituted with one or more independently selected halo, C.sub.1-4 alkyl optionally substituted with one or more independently selected halo, or C.sub.1-4 alkoxy; each R.sup.6, is independently selected from halo, OH, --CN, --NR.sup.8gR.sup.8h, and C.sub.1-4 alkoxy; each R.sup.a is selected from halo, CN, oxo, C.sub.1-4 alkyl or C.sub.1-4 alkyl substituted with one or more independently selected R.sup.7a, C.sub.1-4 alkoxy or C.sub.1-4 alkoxy substituted with one or more independently selected R.sup.7a, --C(.dbd.O)O--C.sub.1-4 alkyl, phenyl, 5-10 membered mono, or fused bicyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, or S, and optionally substituted with one or more independently selected C.sub.1-4 alkyl, and --NR.sup.8aR.sup.8b; each R.sup.b is selected from halo, --CN, C.sub.1-4 alkyl or C.sub.1-4 alkyl substituted with one or more independently selected R.sup.7b, C.sub.1-4 alkoxy or C.sub.1-4 alkoxy substituted with one or more independently selected R.sup.7b, --OC(.dbd.O)C.sub.1-4 alkyl, and --NR.sup.8cR.sup.8d; each R.sup.c is selected from halo, OH, --CN, oxo, C.sub.1-4 alkyl or C.sub.1-4 alkyl substituted with one or more independently selected R.sup.7c, C.sub.1-4 alkoxy or C.sub.1-4 alkoxy substituted with one or more independently selected R.sup.7c, phenyl or phenyl substituted with one or more independently selected halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, --CN, or --NR.sup.9aR.sup.9b, and 5-6 membered monocyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, or S or N, O, or S substituted with one or more independently selected halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, CN, --NR.sup.9cR.sup.9d; each R.sup.d is selected from halo, --CN, --OH, C.sub.1-4 alkyl or C.sub.1-4 alkyl substituted with one or more independently selected R.sup.7d, C.sub.1-4 alkoxy or C.sub.1-4 alkoxy substituted with one or more independently selected R.sup.7d, C.sub.3-7 cycloalkyl, 5-10 membered mono or fused bicyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, or S, and --NH-Phenyl; each R.sup.e is selected from halo, OH, --CN, C.sub.1-4 alkoxy or C.sub.1-4 alkoxy substituted with one or more independently selected R.sup.7e, C.sub.3-7 cycloalkyl, phenyl or phenyl substituted with one or more independently selected halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, CN, and --NR.sup.9eR.sup.9f, and 5-6 membered monocyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S or N, O, and S substituted with one or more independently selected halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, CN, and --NR.sup.9gR.sup.9h; each R.sup.7a, R.sup.7b, R.sup.7c, R.sup.7d, and R.sup.7e is independently selected from halo, OH, --CN, --NR.sup.8iR.sup.8j, and C.sub.1-4 alkoxy; each R.sup.8a, R.sup.8b, R.sup.8c, R.sup.8d, R.sup.8e, R.sup.8f, R.sup.8g, R.sup.8h, R.sup.8i, or R.sup.8j is independently selected from H, and C.sub.1-4 alkyl; each R.sup.9a, R.sup.9b, R.sup.9c, R.sup.9d, R.sup.9e, R.sup.9f, R.sup.9g, or R.sup.9h is independently selected from H, and C.sub.1-4 alkyl; or a pharmaceutically acceptable salt, or a solvate, or a pharmaceutically acceptable salt of a solvate thereof. 2. The method according to claim 1, wherein the compound is according to Formula II: ##STR00583## wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are as described in claim 1. 3. The method according to claim 2, wherein R.sup.4 is C.sub.1-6 alkyl. 4. The method according to claim 1, wherein the compound is according to Formula III: ##STR00584## wherein R.sup.1, R.sup.2, and R.sup.3 are as described in claim 1. 5. The method according to claim 4, wherein R.sup.2 is phenyl substituted with one or more independently selected R.sup.b. 6. The method according to claim 5, wherein R.sup.b is F, Cl, or CN. 7. The method according to claim 1, wherein the compound is according to Formula IV: ##STR00585## wherein Cy is 4-10 membered monocyclic or fused bicyclical heterocycloalkyl comprising one or more heteroatoms independently selected from N, O, and S, R.sup.a is as described in claim 1, and the subscript n is 0, 1 or 2. 8. The method according to claim 7, wherein Cy is azetidinyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, morpholinyl 2-oxa-5-aza-bicyclo[2.2.1]heptanyl, [1,4]oxazepanyl, 2,3-dihydro-1H-isoindolyl, or 1,2,3,4-tetrahydro-isoquinolinyl. 9. The method according to claim 1, wherein R.sup.3 is phenyl, substituted with one or more independently selected R.sup.d groups. 10. The method according to claim 1, wherein R.sup.3 is furanyl, thiophenyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidyl, or pyrazinyl, each of which is substituted with one or more independently selected R.sup.d groups. 11. The method according to claim 10, wherein R.sup.d is F, Cl, OH, or CN. 12. The method according to claim 10, wherein R.sup.d is --CH.sub.3, --CH.sub.2--CH.sub.3, --CH(CH.sub.3).sub.2, --OCH.sub.3, or --OCH.sub.2--CH.sub.3, each of which is optionally substituted with one or more independently selected R.sup.7d. 13. The method according to claim 12, wherein R.sup.7d is F, Cl, OH, CN, or --OCH.sub.3. 14. The method according to claim 1, wherein R.sup.3 is --CH(CH.sub.3).sub.2, --C(CH.sub.3).sub.3, --C(CH.sub.3).sub.2--CH.sub.3, or --C(CH.sub.3)H--CH.sub.2(CH.sub.3), each of which is substituted with one or more independently selected R.sup.e groups. 15. The method according to claim 14, wherein R.sup.e is F, Cl, OH, or CN. 16. The method according to claim 1, wherein R.sup.1 is H. 17. The method according to claim 1, wherein R.sup.1 is --CH.sub.3. 18. The method according to claim 1, wherein the cystic fibrosis is caused by a Class I, II, III, IV, or VI mutation.

Details for Patent 9,867,806

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc.	COTAZYM	pancrelipase	Capsule, Delayed Release	020580	12/09/1996		2033-05-07
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	04/30/2009		2033-05-07
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	06/10/2011		2033-05-07